Curr Opin Endocrinol Diabetes Obes. Oral CEEs, at a daily dosage of 0. Transgender women who retain their gonads but withdraw hormone therapy may experience return of virilization. This is no longer the case, as clinical evidence has showed a strong relationship between ethinyl estradiol and the incidence of deep venous thrombosis General effects include breast development usually to Tanner stage 2 or 3a redistribution of facial and body subcutaneous fat, reduction of muscle mass, reduction of body hair and to a lesser extent, facial hairchange in sweat and odor patterns, and arrest and possible reversal of scalp hair loss.
As infection may also lead to worsening symptoms in patients with myasthenia gravis, clinicians must balance prompt and adequate treatment of infection with the risk that some antibiotics can aggravate
Hormone therapy for transgender patients
Expected effects of this may be similar to non-transgender women experiencing menopause. Aronson 2 March Historische Aspekte, Wirkungsmechanismus, Resultate und aktueller klinischer Stand" [Intramuscular depot estrogens Estradurin in treatment of patients with prostate carcinoma. No significant differences in the other biochemical parameters were evident between the patients receiving estrogen alone and estrogen plus cyproterone acetate. While there are some contradictory data, estrogen alone does not appear to increase the risk of coronary heart disease or breast cancer, unlike the case of estrogen in combination with certain progestins such as levonorgestrel or medroxyprogesterone acetate. In terms of the effects of progestogens on sex drive, one study assessed the use of dydrogesterone to improve sexual desire in transgender women and found no benefit.
The active forms are metabolized primarily in the liver. The study aimed to evaluate the role of menopausal hormone therapy in the prevention of chronic disease. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen". Surgical Management of the Transgender Patient. Raising the dosage of estrogen or adding a progestogen raises the libido of some transgender women. This is likely a result of anti-androgen use, and therefore, providers should consider stopping anti-androgen therapy if and when patients undergo orchiectomy with or without genital confirmation surgery. Received Jul 16; Accepted Nov 8.